Sedation at the end of life - a nation-wide study in palliative care units in Austria by unknown
RESEARCH ARTICLE Open Access
Sedation at the end of life - a nation-wide
study in palliative care units in Austria
Sophie Schur1*, Dietmar Weixler2, Christoph Gabl3, Gudrun Kreye4, Rudolf Likar5, Eva Katharina Masel1,
Michael Mayrhofer1, Franz Reiner6, Barbara Schmidmayr7, Kathrin Kirchheiner8, Herbert Hans Watzke1 and on behalf
of the AUPACS (Austrian Palliative Care Study) Group
Abstract
Background: Sedation is used to an increasing extent in end-of-life care. Definitions and indications in this field are
based on expert opinions and case series. Little is known about this practice at palliative care units in Austria.
Methods: Patients who died in Austrian palliative care units between June 2012 and June 2013 were identified. A
predefined set of baseline characteristics and information on sedation during the last two weeks before death were
obtained by reviewing the patients’ charts.
Results: The data of 2414 patients from 23 palliative care units were available for analysis. Five hundred two (21 %)
patients received sedation in the last two weeks preceding their death, 356 (71 %) received continuous sedation
until death, and 119 (24 %) received intermittent sedation. The median duration of sedation was 48 h (IQR 10–72
h); 168 patients (34 %) were sedated for less than 24 h. Indications for sedation were delirium (51 %), existential
distress (32 %), dyspnea (30 %), and pain (20 %). Midazolam was the most frequently used drug (79 %), followed by
lorazepam (13 %), and haloperidol (10 %). Sedated patients were significantly younger (median age 67 years vs.
74 years, p ≤ 0.001, r = 0.22), suffered more often from an oncological disease (92 % vs. 82 %, p ≤ 0.001, φ = 0.107),
and were hospitalized more frequently (94 % vs. 76 %, p ≤ 0.001, φ = 0.175). The median number of days between
admission to a palliative care ward/mobile palliative care team and death did not differ significantly in sedated
versus non-sedated patients (10 vs. 9 days; p = 0.491).
Conclusion: This study provides insights into the practice of end-of-life sedation in Austria. Critical appraisal of these
data will serve as a starting point for the development of nation-wide guidelines for palliative sedation in Austria.
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Background
Adequate symptom relief is a central aspect of medical
care in all patients, especially those with incurable diseases
[1]. However, satisfactory control of symptoms may be dif-
ficult as an illness progresses and patients approach the
end of life [1–3]. Despite intensive efforts to manage such
problems, physical or psycho-existential symptoms may
remain uncontrollable in some patients [1, 3, 4]. There-
fore, sedation at the end of life is a valid and increasingly
used therapeutic intervention to relieve the burden of se-
vere and refractory symptoms [1, 5–7].
According to the European Association for Palliative
Care (EAPC), palliative sedation (PS) is defined as the
‘monitored use of medications intended to induce a state
of decreased or absent awareness (unconsciousness) in
order to relieve the burden of otherwise intractable suffer-
ing..’ [6]. Importantly, PS should be used as last resort at
the end of a patient’s life, with the intent of minimizing
symptoms in a manner that is ethically acceptable to the
patient, caregivers and all healthcare providers involved
in the sedation process [6, 7].
Although PS is used increasingly often in terminally ill
patients, healthcare professionals are still confronted
with numerous clinical and ethical challenges [1, 8].
Besides, literature indicates a considerable heterogeneity
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with regard to the definition of PS, its frequency, and
indications for its use [9, 10].
In recent years, a number of international medical
associations [6, 11], national bodies [12, 13], and local
institutions [14, 15] have tried to develop guidelines and
policies with the aim of defining PS [9, 16]. To date
however, no randomized studies have been focused on
these aspects and current assertions are based on expert
opinions and case series. Whereas the practice of PS has
been a subject of research in many countries [17–22], it
has not been investigated systematically in Austria.
The present study included the data of more than
2424 patients being cared for at Austrian palliative care
wards and mobile palliative care teams. The data were
analyzed with regard to the prevalence of intermittent
and continuous sedation therapy within the last two
weeks of the patients’ lives. In addition we compared se-
dated and non-sedated patients in terms of clinical char-
acteristics and the duration of admission to a palliative
care ward or treatment by a mobile palliative care team.
Methods
Setting and participants
The study was performed as a retrospective chart review
in palliative care wards and mobile care teams in
Austria. Data were obtained from the medical records of
patients who had died at one of the palliative care units
between 1st June 2012 and 31st May 2013. Each pallia-
tive care unit was asked to state the number of patients
treated in the study period, the number of patients who
had died, and the number of patients with available
medical records.
The observation period encompassed the last two
weeks of the patients’ lives. Clinical characteristics (age,
sex, underlying disease: oncological vs. non-oncological,
date of admission and death) as well as co-medication
(non-opioids, opioids, antibiotics, deep venous throm-
bosis prophylaxis, artificial hydration and nutrition)
given during the last three days before death were re-
corded for all patients.
Sedation therapy at the end of life was defined as any
sedating intervention initiated in the last two weeks of
the patient’s life and given continuously until his/her
death (minimal duration one hour), or as intermittent
sedation for more than 24 h, even when it was not given
at the time of the patient’s death. In order to exclude
sedation as a side effect of other medications acting on
the central nervous system (such as sleeping medication
or anticonvulsants), the palliative care units were
instructed upfront at a meeting, informed of the study
protocol, and sent an accompanying letter.
Sedation practice in each patient was recorded in a
three-page case report form (CRF). Each palliative care
unit had to mention whether they had an instruction
manual for indications, procedure, and monitoring at
their site.
The following parameters were recorded in patients who
received sedation: indication(s) for sedation, medication,
continuity of sedation (continuous versus intermittent),
route of administration (intravenous, subcutaneous), dose
(in the first and last 24 h of sedation) and the total duration
of sedation (days/hours).
The study protocol was approved by the ethics
committee of the Medical University of Vienna (2060/
2013).
Statistical analysis
Categorical data are presented descriptively with abso-
lute numbers and percentages; missing values were
below 1 % unless specified otherwise.
For metric data, the median and interquartile ranges
(lower and upper quartiles) are reported, based on skewed
distribution.
Categorical data were tested using Pearson’s Chi-
square tests, metric data with the parameter-free Mann–
Whitney U-test in independent samples, and Wilcoxon’s
matched-pair signed-rank test in dependent samples.
The significance level was set two-sided at 5 %; p-values
were corrected for multiple tests with the Bonferroni-
Holm method. For the estimation of effect sizes in
significant results, Pearson’s correlation coefficient (r) or
the phi coefficient (φ) are reported, based on the follow-
ing ratings: 0.1 = small, 0.3 =moderate, and 0.5 = large
effect size.
For time to event analysis, the days between admission
to a palliative care ward/start of care by a mobile pallia-
tive care team and death were compared between
sedated and non-sedated patients using the Breslow
(generalized Wilcoxon) test [23]. In a subgroup analysis
in order to find a potential difference between patients
receiving continuous or intermittent sedation the Bre-
slow (generalized Wilcoxon) test was also used.
Analysis was performed with the Statistical Package
for the Social Sciences IBM SPSS v.22 (Armonk, NY:
IBM Corp).
Results
Twenty-three of 31 (74 %) palliative care wards and mo-
bile care teams in Austria participated in this study. A
total of 5465 patients were treated between June 2012
and June 2013 at these units. 2672 (49 %) patients died
during their hospital stay or the time period treated by a
mobile palliative care team and were therefore eligible
for the evaluation of sedation during the last two weeks
of their lives. The data of 2414 (90 %) deceased patients
were available and could be included in the subsequent
analysis (Fig. 1).
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Fig. 1 CONSORT diagram of the study population




(n = 502, 21 %)
Non-sedated patients




Age in years in median (IQR) 73 (64–82) 67 (56–75) 74 (65–83) ≤0.001* ≤0.001* r = 0.220
Time between admission and death
in days in median (IQR)
9 (4 – 20) 10 (5–19) 9 (4–22) 0.491 0.491 -
n % n % n %
Sex 0.014* 0.070 φ = 0.051
Female 1251 52 % 236 47 % 1015 53 %
Male 1158 48 % 266 53 % 892 47 %
Oncological disease 2027 84 % 461 92 % 1566 82 % ≤0.001* ≤0.001* φ = 0.107
Other diseases 372 15 % 40 8 % 332 17 %
Type of palliative care ≤0.001* ≤0.001* φ = 0.175
Hospital based 1930 80 % 470 94 % 1460 76 %
Mobile 484 20 % 32 6 % 452 24 %
Co-medication in the last three days of life
Opioids pain medication 2213 92 % 484 96 % 1729 90 % ≤0.001* ≤0.001* φ = 0.100
Non-opioid pain medication 1271 53 % 240 48 % 1031 54 % 0.032* 0.128 φ = 0.044
I.v. hydration 1018 42 % 242 48 % 776 41 % 0.001* 0.006* φ = 0.077
Artificial nutrition 624 26 % 114 23 % 510 27 % ≤0.001* ≤0.001* φ = 0.099
Antibiotic treatment 404 17 % 96 19 % 308 16 % 0.088 0.176
DVTP medication 571 24 % 133 27 % 438 23 % 0.071 0.213
Abbreviations: N number, IQR interquartile range, I.v. intravenous, DVTP deep venous thrombosis prophylaxis
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Patient characteristics: overall cohort
The patients’ median age was 73 years (IQR 64–82
years); 52 % were female. One thousand nine hundred
thirty (80 %) patients were treated at hospital-based pal-
liative care wards while 484 (20 %) were treated at home
by mobile palliative care teams.
The median duration from admission to a palliative
care ward/mobile palliative care team until death was
9 days (IQR 4–20 days). Ninety-four patients (4 %) died
on the day of admission to a palliative care ward/their
first contact with the mobile palliative care team. Two
thousand forty two patients (85 %) underwent care at
the palliative care ward during the last month before
their death or were treated for at least one month by the
mobile palliative care team. Two thousand twenty seven
patients (84 %) had a malignant disease (Table 1).
In the last two weeks before death, 502 patients (21 %)
were sedated. The percentage of sedated patients varied
markedly across the participating study centers (range
0–54 %; Fig. 2). Further characteristics in respect of the
patients’ co-medication in the last three days of their
lives are shown in Table 1.
Differences between sedated and non-sedated patients
Sedated patients were significantly younger (median age
67 years vs. 74 years, p ≤ 0.001, r = 0.22), suffered more
often from oncological disease (92 % vs. 82 %, p ≤ 0.001,
φ = 0.107), and were hospitalized more often (94 % vs.
76 %, p ≤ 0.001, φ = 0.175). Sedated patients received
significantly more opioids (96 % vs. 90 %, p ≤ 0.001, φ =
0.100), more intravenous hydration (48 % vs. 41 %, p =
0.006, φ = 0.077), and less artificial nutrition (23 % vs. 27 %,
p ≤ 0.001, φ = 0.099). The details are listed in Table 1.
The median number of days from admission to a pal-
liative care ward/start of care by a mobile palliative care
team until death did not differ significantly between se-
dated and non-sedated patients (10 vs. 9 days; p = 0.491;
Fig. 3). In a subgroup analysis, no difference was
observed between patients receiving continuous and
intermittent sedation regarding the number of days from
admission to a palliative care ward/start of a mobile care
team until death (p = 0.259).
Documentation of sedation at study sites
Twenty-one contributing palliative care units (91 %)
used an explicit documentation form for sedation, 14
(67 %) followed a written instruction manual, and 6
(29 %) a written monitoring form.
Sedation practice in Austria
Continuous sedation until death was given to 356 (71 %)
of all sedated patients, and intermittent sedation to 119
(24 %) (missing information for 5 %). The median dur-
ation of sedation was 48 h (IQR 10–72 h); 168 patients
(34 %) were sedated for less than 24 h and five patients
for more than three weeks.
Indications for sedation were delirium (n = 254, 51 %),
existential distress (n = 159, 32 %), dyspnea (n = 151,
30 %), pain (n = 99, 20 %), and other individual reasons
(n = 56, 11 %) (Table 2). Two or three indications for
Fig. 2 Sedation prevalence in the participating Austrian palliative care centers
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sedation were documented in 36 and 8 % of the patients,
respectively.
Midazolam was most frequently used for sedation (n =
395, 79 %) followed by lorazepam (n = 66, 13 %), halo-
peridol (n = 51, 10 %), levomepromazine (n = 17, 3 %),
diazepam (n = 14, 3 %) and propofol (n = 13, 3 %)
(Table 2). The majority of patients (n = 443, 88 %) re-
ceived only one drug; 53 patients (11 %) received two
drugs. Women received more than one drug for sedation
(p < 0.004) significantly more often than men. No statis-
tical difference was noted in regard of other clinical
variables such as age, diagnosis, and the overall duration
of hospitalization.
The routes of administration of sedation were as fol-
lows: continuous intravenous (i.v.) administration in 253
patients (50 %), i.v. bolus in 209 (42 %), continuous sub-
cutaneous (s.c.) administration in 56 (11 %), and an s.c.
bolus in 100 patients (20 %) (Table 2).
Three hundred nineteen patients (68 %) received
medication for sedation via one route of administration,
whereas 146 (31 %) received the medication via two
routes.
A significant increase in dose from the first to the last
24 h was only registered for midazolam (median drug
dose in mg: 15 vs. 24, p ≤ 0.001); no significant dose in-
crease was noted for any other drug.
Discussion
This present study reveals the first insight about the
current prevalence and practice of sedation in Austrian
palliative care wards and mobile care teams. The follow-
ing findings of our study deserve particular attention.
To our knowledge to date this is by far the largest
study conducted on sedation at the end of life [1, 24].
Twenty-three of 31 (74 %) Austrian palliative care wards
and mobile care teams contributed to this study. As
these wards and mobile care teams are dedicated pallia-
tive care units involved in a nation-wide project on the
development of palliative care in Austria, with identical
structural requirements and procedural standards, our
data provide a clear picture of palliative sedation in
Austria. All mobile palliative care units who participated
in this study were associated with a hospital based pallia-
tive care ward providing access to a multidisciplinary
care team. According to the Austrian palliative care
system patients have the possibility to receive mobile
care according to their personal preferences as well as
prevailing mobile care disposability.
The rate of sedation registered in our cohort (21 %) is
at the lower end of sedation rates reported previously in
a systematic review by Maltoni et al. [24]. However, sed-
ation rates varied very markedly in the participating
study centers (range 0–50 %). As in Austria for the use
of palliative sedation no stringent guidelines exist, this
variation is indicative of a lack of national consensus in
this sector. Nation-wide recommendations will be
needed in the near future in order to enhance safety in
clinical practice.
As reported in the published literature, pain, dyspnea,
agitated delirium, and anxiety are among the most com-
mon symptoms of cancer patients approaching the end
Fig. 3 Actuarial Kaplan-Meier estimates in 2414 patients with or without sedation
Schur et al. BMC Palliative Care  (2016) 15:50 Page 5 of 8
of live [24, 25]. Overall, the prevalence of refractory
symptoms requiring sedation ranges from 10 to 50 %,
with a median estimate of 20–30 % [24, 26, 27] compar-
able to our data from Austrian palliative care units
(21 %). Consistent with previous findings, delirium was
the most common indication for palliative sedation
followed by existential distress, dyspnea and pain [24].
Furthermore, as reported previously the majority of all
patients are assessed as suffering from more than one
symptom [26] and in our study cohort as well close to
half to all patients (44 %) were documented with two or
three indications for sedation.
Approximately one third of our patients received sed-
ation because of existential distress. As in other reports
[17, 21, 28], these patients were significantly younger
(p ≤ 0.001) than those who were sedated for other rea-
sons, but did not differ in terms of gender and the
duration of hospitalization/treatment by a mobile pallia-
tive care team.
According to the EAPC, sedation may occasionally be
considered in patients with severe psychological symptoms
such as refractory depression, anxiety, demoralization or
existential distress [6]. However, sedation for the manage-
ment of existential distress is still controversially discussed
in the literature [1, 6, 7]. The term existential distress is
complex since it includes several symptoms such as feelings
of meaninglessness/worthlessness/dependency and isola-
tion, fear or panic of impending death, lack of social sup-
port, as well as spiritual issues. Furthermore existential
distress may be a dynamic phenomenon in the course of a
disease. As it does not necessarily indicate an advanced
stage of psychological deterioration, the truly refractory na-
ture of the symptoms cannot be established conclusively [1,
6, 7]. Due to these issues palliative sedation for existential
distress, should be considered cautiously, and only after
other interventions have been exhausted as determined by
a multidisciplinary team [1, 6, 7].
The rather high rate of existential distress in our study
may be explained by several factors. First, given the am-
biguous definition of existential distress and its clinical
symptoms [1, 6, 7], no standardized definition of the
term was provided to the centers participating in the
study. Secondly, the study was conducted by retrospect-
ive chart review, allowing multiple indications for sed-
ation in a single patient. From the clinical perspective it
is feasible that existential stress occurs when a specific
physical symptom is untreatable. As visible from our
data nearly half of all patients (43 %) in our study cohort
were documented with two or three indications for sed-
ation; this would account for the high prevalence of ex-
istential stress as an indication for sedation in the
present study.
Based on the large majority of reports, benzodiaze-
pines remain the most favored class of sedatives in pal-
liative care [1, 6, 24, 28–30]. Midazolam was the drug of
first choice in our study population. Effective alternatives
such as haloperidol, levomepromazine and propofol [1,
6, 24] played a minor role and were largely used in con-
junction with specific indications.
Midazolam, a short-acting benzodiazepine, has anti-
convulsant, muscle-relaxing and anxiolytic properties
[29]. Psychotropic drugs such as haloperidol or
levomepromazine may be more appropriate for the
management of delirium, and may be used in com-
bination with benzodiazepines [24, 31]. Propofol is
liable to cause rapid unconsciousness [32] and may
be an effective last-line option when all other medica-
tions have failed [24, 32].
In our patients, women received a single drug for pal-
liative sedation significantly more often (p < 0.004*), but
no statistical difference was registered for other variables
Table 2 Characteristics of sedation in sedated patients (n = 502)
Missing information (%)
Median sedation
time in hours (IQR)
48 (10–72) 12 (2 %)
n % 13 (3 %)
Type of sedation 27 (5 %)
Continuous 356 71 %
Intermittent 119 24 %
Indication for sedation
Delirium 254 51 % 18 (4 %)
Existential distress 159 32 % 18 (4 %)
Dyspnea 151 30 % 17 (3 %)
Pain 99 20 % 18 (4 %)
Other individual reasons 56 11 %
Not verifiable 34 7 % 17 (3 %)
Drug used for sedation
Midazolam 395 79 % 2 (<1 %)
Diazepam 14 3 % 2 (<1 %)
Propofol 13 3 % 2 (<1 %)
Propthipendyl 3 1 % 2 (<1 %)
Levomepromazin 17 3 % 2 (<1 %)
Dihydrobenzperidol 2 <1 % 2 (<1 %)
Lorazepam 66 13 % 2 (<1 %)
Clonazepam - - 2 (<1 %)
Haloperidol 51 10 % 2 (<1 %)
Thiopental - - 2 (<1 %)
Type of administration
i.v. bolus 209 42 % 36 (7 %)
i.v. continuously 253 50 % 36 (7 %)
s.c. bolus 100 20 % 36 (7 %)
s.c. continuously 56 11 % 36 (7 %)
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such as age, diagnosis, and the overall duration of
hospitalization.
The median duration of sedation in our cohort was
within the reported range (two days) [17, 24, 28]; only
five patients were sedated for more than three weeks.
We also assessed co-medications during the last three
days of the patients’ lives, which provided even greater
insight into end-of-life practice in Austrian palliative
care units. Overall, the majority of patients who died at
a palliative care unit received non-opioids and opioids
(53 and 92 %). A substantial number received antibiotics
(17 %), prophylaxis for deep vein thrombosis (24 %),
artificial hydration (42 %) and nutrition (26 %). Sedated
patients received significantly more opioids and artificial
hydration, but less artificial nutrition.
Importantly, opinions, practices and decisions regard-
ing the administration of hydration and/or artificial nu-
trition vary widely in the published literature. These
should be viewed independent of the decision for or
against palliative sedation [1, 6, 7]. The variance of opin-
ions and practices probably reflects the heterogeneity of
patients, caregivers, and clinicians. Consensus must al-
ways be achieved together with the patient and/or family
members, based on the patient’s best interests [1, 6].
In conformity with other studies [24, 28], the median
number of days between admission to a palliative care
ward (mobile palliative care team) and death in our co-
hort did not differ significantly between sedated vs. non-
sedated patients (10 vs. 9 days; p = 0.491). Importantly,
in a further subgroup analysis to exclude the potential
bias of sedation level (continuous vs. intermittent), no
difference was observed between patients receiving con-
tinuous and intermittent sedation regarding the number
of days of hospitalization until death (p = 0.259). Sed-
ation may therefore be considered an appropriate clin-
ical intervention to relieve terminally ill patients of their
intractable symptoms. To the best of our knowledge, it
does not exert a negative impact on the patient’s
survival.
Limitations and strengths of the study
Undoubtedly, the retrospective design of our study
leaves many important questions unanswered in regard
of sedation at the end of a patient’s life.
Owing to the retrospective design, this study provides
no more than a rough estimate of the effect of palliative
sedation on actual survival and thus cannot reliably
prove or reject the life-shortening effect of sedation. A
randomized controlled trial would be needed to address
this question [24, 28]. However, a trial design of this na-
ture would leave the control group without a treatment
option in the event of intractable symptoms, and would
therefore be ethically unjustifiable [1, 24].
Another important limitation of our study is the fact
that no operational definition on the term existential
distress was provided to the participating study centers.
Besides, the option of main and secondary indications
was not taken into account because the units were per-
mitted to use several indications for sedation at a time.
As mentioned earlier, we defined sedation therapy at
the end of life as any type of sedation initiated in the last
two weeks of a patient’s life and given continuously until
death (minimal duration one hour), or as intermittent
sedation in the last two weeks of a patient’s life for a
duration of more than 24 h, even when the sedation was
not administered when the patient died. Further guided
instructions concerning deep continuous and partial
intermittent sedation were not provided by the study
team; these aspects were left to the discretion of the
treating physician.
Long-term observation of the timing of co-medications
was beyond the scope and feasibility of the retrospective
study design. For reasons of practicability we only regis-
tered the presence of co-medication in the last three days
before death. Besides, important issues relating to pallia-
tive sedation, such as decision-making, the intensity of
sedation, and the incorporation of family and team mem-
bers in the decision-making process could not be
addressed.
Our study monitored the use of sedatives at the end of
patients’ lives in palliative care units in Austria, but de-
liberately did not use the term ‘palliative sedation’ in the
study protocol because many palliative care units em-
ploy sedation at the end of life with the intent of pallia-
tive sedation, but do not have explicit comprehensive
protocols for palliative sedation. Since the study protocol
was designed to exclude other indications for sedation at
the end of life (such as insomnia), but asked for specific
sedation practices typically used for palliative sedation,
we conclude that the data do reflect actual palliative sed-
ation practice at these units.
The strengths of the study include the large number of
studied patients, the high rate of recruitment at Austrian
palliative care wards and mobile care teams, and the
small number of incomplete data. Our database was de-
rived from palliative units, which have identical struc-
tural requirements and procedural standards, and
therefore yielded a homogenous study sample.
Conclusion
To date this is the largest study on sedation at the end
of life and provides preliminary insights into the preva-
lence of, and indications for, palliative sedation in
Austria. It supports previous data which suggest that
palliative sedation, when properly administered, is an ap-
propriate therapeutic procedure that does not shorten
the period of time from admission to a palliative care
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ward/mobile care team until death. In order to minimize
variation and enhance safety in clinical practice, imple-
mentation of a nation-wide guideline for the use of pal-
liative sedation will be developed in Austria.
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